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50 years of vaccine research
RSV is a worldwide burden (64 million infections/yr, 
160’000 deaths/year) 
RSV was first isolated in 1956 (Morris et al.).
No licenced vaccine available
RSV weakly immunogenic
Enhanced disease associated with a formalin-inactivated
vaccine (Kapikian et al, 1969, Kim et al, 1969)
Subunit vaccine promising
F and G proteins induce neutralizing Ab (Walsh et 
al,1987)
How to produce RSV-F ?
Production of recombinant RSV-F (rRSV-F) in 
mammalian cells by Transient Gene Expression (TGE)
Correct folding, assembly, and post-translational
modifications
Scalable and simple process
Rapid and inexpensive
Production of viral RSV-F (vRSV-F)
low viral titers in cell culture
biosafety problems
Objectives
1. Production of rRSV-F by transient gene
expression in mammalian cells.
2. Scale up of the manufacturing process of 
rRSV-F for animal studies.
3. rRSV-F in virosomes : Animal experiments.
Establish a manufacturing process for rRSV-F :
RSV-F : a trimeric membrane glycoprotein
Morton et al, 2003
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DNA and Transfecting Agent amounts
Optimal conditions yielded 30 mg/L of rRSV-F 








1. Production of rRSV-F by transient gene
expression in mammalian cells
30 mg/L at 10-mL scale …











12 mg of purified rRSV-F were produced for 











2. Scale up of the manufacturing process of 
















Immunization of BALB/c mice
7.5 μg RSV-F/dose
rRSV-F-virosome i.m.




















Neutralization of RSV by BALB/c mice sera
Animal challenge in cotton rats has been performed




3. rRSV-F in virosomes : Animal experiments
Conclusion
1. We developed a scalable process for the 
production of rRSV-F by transient gene expression 
in mammalian cells.
2. Transient gene expression allowed the rapid
production of pure rRSV-F for animal studies. 
3. rRSV-F in virosomes induces neutralizing
antibodies in BALB/c mice.
Go forward with transient technology
Transient gene expression :
for animal studies
…for clinical trials ?
… for production ?
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